Your browser doesn't support javascript.
loading
Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide.
Deliliers, Giorgio Lambertenghi; Annaloro, Claudio; Marconi, Maurizio; Soligo, Davide; Morandi, Paolo; Luchesini, Camilla; Tagliaferri, Elena; Della Volpe, Aldo.
Afiliación
  • Deliliers GL; Dipartimento di Ematologia, Centro Trapianri di Midollo, Ospedale Maggiore IRCCS, Via Francesco Sforza 35, 20122, Milan, Italy. giorgio.lambertenghi@unimi.it
Leuk Lymphoma ; 43(10): 1957-60, 2002 Oct.
Article en En | MEDLINE | ID: mdl-12481891
Although high-dose cyclophosphamide (HD-CTX) is commonly used as a mobilising regimen for autologous peripheral blood stem cell (PBSC) collection, significant morbidity and insufficient harvesting may complicate the procedure. Alternative regimens and lower doses of cyclophosphamide (CTX) have been investigated as possible ways of overcoming these difficulties. Low-dose CTX (1.5 g/m2) was administered to 102 lymphoma patients as an autologous PBSC mobilising regimen. The collection of 6 x 10(6) CD34+ cells/kg was chosen as the target of the apheresis sessions, whereas 3 x 10(6)/kg were considered the minimum necessary to perform autologous stem cell transplantation (ASCT) safely. The apheretic sessions were started a median of eight days after CTX administration; a median of two aphereses was required. More than 6 x 10(6) CD34+ cells/kg were collected from 78 patients, between 3 and 6 x 10(6)/kg from 19, and fewer than 3 x 10(6)/kg from 5, two of whom underwent bone marrow harvesting and one a successful second PBSC harvesting session using the same mobilising regimen. Eighty-two patients underwent autografting, six of whom received a second transplant after relapse (five using autologous PBSCs coming from the first apheretic course). Low-dose CTX proved to be a safe and effective regimen for autologous PBSC mobilization and also compared favourably with alternative regimens in terms of the rate of harvesting insufficiency. This does not imply that low-dose CTX is the best mobilising regimen for all patients, and the identification of prognostic factors predicting mobilising potential may help in choosing the best individualised regimen.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucaféresis / Movilización de Célula Madre Hematopoyética / Ciclofosfamida / Trasplante de Células Madre de Sangre Periférica Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2002 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucaféresis / Movilización de Célula Madre Hematopoyética / Ciclofosfamida / Trasplante de Células Madre de Sangre Periférica Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2002 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos